← All tickers

Is ALLO Worth Buying in 2026?

Allogene Therapeutics, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-23

Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.88% over 10 days); RSI 64 — healthy momentum range; strong 1-year return of +86.6%. Currently 53.1% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

ALLO is in a confirmed uptrend, trading above both its 50-day ($1.98) and 200-day ($1.92) moving averages. An RSI of 63.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +86.6% compares to +20.5% for SPY (beat the market by 66.1%). The current 53.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $18,661 today
vs. S&P 500 (SPY) — same period beat market by 66.1%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($1.92)
✓Above 50-day MA ($1.98)
✓RSI(14) neutral zone (30–70) — currently 63.7
✓Positive return (+86.6%)
!Within 10% of period high (−53.1%)
Period Range $2.09
$1.04 $4.46
RSI (14) 63.7
0 · OversoldOverbought · 100

Key Metrics

Price$2.09
Period Return+86.6%
Period High$4.46
Period Low$1.04
Drawdown−53.1%
MA-50$1.98
MA-200$1.92
RSI (14)63.7
Avg Volume (30d)5.8M
vs. SPYbeat by 66.1%
Return Rank#151 of 999

Trade ALLO

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers